The New Science Of Three-Parent Babies
By Tom Ashbrook,
NPR On Point
| 02. 26. 2014
[With CGS's Marcy Darnovsky]
Day two today of F.D.A. hearings on what you may have seen described in headlines as “three-parent babies.” The genetic material of three adults combined to make one healthy baby. Mom’s nuclear D.N.A., dad’s sperm, and mitochondrial D.N.A. from a donor, to avoid inheritable disease. Backers say this reproductive technology will spare families from passing down suffering. Maybe extend fertility for older moms. Critics say this is the gateway to genetically modified human beings, high-tech eugenics, dystopia. This hour On Point: science, ethics, reproduction, and D.N.A. times three.
– Tom Ashbrook
Guests
Dina Fine Maron, associate editor at Scientific American. (@Dina_Maron)
Stefani Bush, singer, blogger and patient advocate. (@HopeRisingMusic)
Marcy Darnovsky, executive director of the Center for Genetics and Society.
Dr. James Grifo, program director of New York University’s Fertility Center.
From Tom’s Reading List
Scientific American: Making Babies with 3 Genetic Parents Gets FDA Hearing — “Reproductive technologies that marry DNA from three individuals will receive a trial in the court of public opinion this week. Such technologies may hold promise for averting certain genetically...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...